New Cancer Cure-Bio Co., Ltd

New Cancer Cure-Bio (NCC-Bio) is a South Korean biotechnology company dedicated to developing first-in-class cancer therapeutics by targeting novel oncogenic drivers. The company's core research focuses on AIMP2-DX2, a splicing variant of the AIMP2 protein that is highly expressed in various cancers and correlates with poor patient prognosis. NCC-Bio is leveraging this biological insight to develop a diverse pipeline that includes small molecule inhibitors, CAR-T cell therapies, and CAR-NK cell therapies specifically designed to treat refractory solid tumors. Founded by Professor Kim Sung-hoon, a global authority on aminoacyl-tRNA synthetases, the company aims to provide innovative solutions for patients with limited treatment options, particularly in non-small cell lung cancer.